The Primary Disease Process Being Studied is Shoulder OA and the Effect of an All Polyethelene Glenoid Component on Shoulder ArthroplastyPhase 4NCT01313741
This is a 2 Year Follow up Clinical and Radiographic Analysis of a Novel All Polyethelene Glenoid Component in Standard Total Shoulder Arthroplasty.
A Phase 4 study testing Shoulder arthroplasty with anchor peg glenoid in people with The Primary Disease Process Being Studied is Shoulder OA and the Effect of an All Polyethelene Glenoid Component on Shoulder Arthroplasty, run by Knoxville Orthopedic Clinic at 1 site in United States.
Trial summary
Two hundred patients will be analyzed both clinically (via validated outcomes measures) and radiographically (via 2 sets of standard radiographs) to determine the survival and degree of bone in growth of a novel all polyethelene glenoid component used in a standard FDA approved shoulder arthroplasty system. Read more about this study
- Who is it for?
- Ages 40 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- The Primary Disease Process Being Studied is Shoulder OA and the Effect of an All Polyethelene Glenoid Component on Shoulder Arthroplasty
- What is being tested?
- Shoulder arthroplasty with anchor peg glenoid
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2011to Apr 2012
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Inclusion Criteria: all patients with standard OA who had a shoulder arthroplasty with an anchor peg glenoid -
Exclusion Criteria:Any paient who had a concomitant rotator cuff tear, infection, revision or previous arthroplasty.
-
Trial locations and contacts
1 site in 1 country.
United States1 site
Knoxville Orthopaedic Clinic
Knoxville, Tennessee, 37922
Edwin E Spencer Jr, MD, 865-450-1227, spencer9882@comcast.net
Edwin E Spencer Jr, MD
About this study
Two hundred patients will be analyzed both clinically (via validated outcomes measures) and radiographically (via 2 sets of standard radiographs) to determine the survival and degree of bone in growth of a novel all polyethelene glenoid component used in a standard FDA approved shoulder arthroplasty system.
Read the detailed description
Methods and Materials: The standard of care in my practice and most practices is to have arthroplasty patients return for an annual clinical and radiographic evaluation. We are asking our patients that choose to enroll in the study to simply return for routine "standard of care" follow up. The only deviation from this standard of care is the method by which we obtain the xrays. In this study we will obtain true AP (anterior/posterior) and axillary views on there return visit. These are our normal "standard of care" xrays. The only difference is that we are going to obtain these Xrays using fluoroscopic guidance. The reason we are using fluoroscopic guidance is that we want to make sure that the xrays are perfect with the beam oriented tangential to the backside of the glenoid. This will allow us to see any lucencies behind the glenoid and allow us to truly assess for any loosening. Standard Xrays attempt to have the beam oriented tangential to the glenoid but just small deviations can underestimate any potential lucent lines. This will expose the study subjects to small amounts of radiation that would be outside the "standard of care". The patients will be informed of this and the dose recorded. The fluoroscopy procedure will take about 15-20 minutes, but the total radiation exposure for the activities performed will be up to, but not more than three minutes. The total radiation will be less than 3 rem. A licensed radiology technologist (RT) employed by the hospital will perform the fluoroscopy procedures and the Xrays. Jeff Jarnagin PA or Edwin Spencer MD will be present at all times during the fluoroscopy procedure. Both Dr Spencer and Jeff Jarnagin have been involved in other similar studies and have completed "training in human research subject protection". Subjects will be provided proper shielding (lead apron) throughout the activities. The licensed radiology technologist at the hospital will have the final responsibility for providing proper shielding.
As with every clinical study, there may be some risks. Since the fluoroscope emits X-rays, subjects will be exposed to radiation. During fluoroscopy, the actual dose of radiation exposure that will be administered, is within minimal risk limits and will be much lower than those known to produce detectable health effects. For this study, the fluoroscopy machine will be on for up to, but not more than, 3 minutes total and the amount of radiation will not exceed 3 rem which includes the radiation from the standard Xrays. According to published literature, exposure risks below 5-10 rem are minimal. Health effects have not been consistently demonstrated for radiation exposure below 10 rem.
Subjects will also fill out 2 data sheets. One is for the PENN score and the other is for the ASES (Association of Shoulder and Elbow Surgeons) score which are validated clinical outcomes measures. These forms are routinely filled out at their annual clinical visits and are considered standard of care.
Data Analysis: The radiographs will be independently evaluated by 2 different board certified radiologists blinded to the clinical results and names of the patients. The films will be re-evaluated by each radiologist (they will be blinded to their initial reading) and the average of their results will be recorded. The clinical ASES and PENN scores will be recorded and differences in the preoperative and postoperative scores will be reported. Statistical analysis such as a students t test is not necessary as we are not comparing two groups however simple descriptive statistics will be used to report the change in ASES and PENN scores and most importantly the presence or absence of lucent lines and location of any lucencies. The lucent lines will be graded according to the method developed by Lazarus et al.4 The medical records and Xray data will be kept as confidential as possible under current local, state, and federal laws. The researchers will examine the medical records for information related to both of the shoulders and the study data. The medical records that identify the subject and the consent form will be reviewed by the researchers. The results of this research project may be presented at meetings or in publications. The identity of the subject will not be disclosed in any presentation or publication.
The Xrays will be stored in a secure place at the Knoxville Orthopaedic Clinic. These Xrays will be accessible by only approved personnel. They will be kept indefinitely for the possibility of future use in research or publications.
Personnel who will have access to your information include:
- Jeff Jarnagin PA (Assistant to Dr Spencer)
- Dr. Edwin Spencer, PI (Orthopaedic Surgeon)
Risk Analysis: The only risk involved is the extra amount of radiation required to obtained the floroscopically guided Xrays. As stated above the maximum amount of radiation is 3 rem which includes the radiation from the standard Xrays. According to published literature, exposure risks below 5-10 rem are minimal. Health effects have not been consistently demonstrated for radiation exposure below 10 rem. To protect the subjects a licensed radiology technologist (RT) employed by the hospital will perform the fluoroscopy procedures and the Xrays. Jeff Jarnagin PA or Edwin Spencer MD will be present at all times during the fluoroscopy procedure. Subjects will be provided proper shielding (lead apron) throughout the activities. The licensed radiology technologist at the hospital will have the final responsibility for providing proper shielding.
The benefits to the patient is for the researchers (and readers of any published data) to garner a better understanding of the best method to resurface the glenoid in a TSA. Many patients require bilateral operations and therefore it could directly benefit a few patients but essentially this project is designed to gather information for the greater good of all patients who require a TSA.
Subject Identification, Recruitment And Consent: Subjects will be identified by a unique identification number analogous to that used by the Knoxville Orthopaedic Clinic. Subjects will be called by either Dr Edwin E Spencer Jr MD (PI) or his assistant Jeff Jarnagin PA and asked to be involved or participate. The patients will be made aware that participation in the study is completely voluntary and that participation does not affect their future access to care by Dr Spencer. Informed consent will be reviewed over the phone and in person when they come in for Xrays by Dr Spencer or his assistant Jeff Jarnagin PA. Attached is our consent form. Once the subject has completed the xray evaluation and completed the clinical forms, they will be paid the $50 stipend. The subject will incur no cost for participation in the study. Insurance carriers will not be billed for any part of the study. The money for the patients will come from the study sponsor DePuy Inc. The xrays including the floroscopy and radiologists' readings will be paid for by the study sponsor DePuy. The surgeon, Dr Spencer, will not be paid for his time and effort and is donating his time to science and the greater good.
- Being tested
- Shoulder arthroplasty with anchor peg glenoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Shoulder arthroplasty with anchor peg glenoidDevice
Shoulder arthroplasty with anchor peg glenoid
| Study group | Role | What they receive |
|---|---|---|
| Single arm shoulder arthroplasty | Experimental | Not described Receives: Device: Shoulder arthroplasty with anchor peg glenoid |
What is being measured
The primary outcome is the main question the study is designed to answer.
ASES Scores
Accepted validated clinical outcome measure
Measured: Every 3 months
PENN Score
Accepted validated outcome measure
Measured: 3 months
Radiographic integration of component
Two sets of radiographs will be obtained to look for any signs of loosening and for bony integration of the component
Measured: 2 weeks, 6 weeks, 3 months, 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2011 (estimated)
- Study startApr 2011
- Primary completionApr 2012 (estimated)
- Study completionApr 2012 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for The Primary Disease Process Being Studied is Shoulder OA and the Effect of an All Polyethelene Glenoid Component on Shoulder ArthroplastyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Knoxville Orthopedic Clinic
- Sponsor type
- University, hospital or other
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01313741
- Sponsor's protocol ID
- Anchor Peg Study
- Status last verified
- Mar 2011
- First submitted
- 10 Mar 2011
- Last updated
- 14 Mar 2011
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Mar 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- This is a 2 Year Follow up Clinical and Radiographic Analysis of a Novel All Polyethelene Glenoid Component in Standard Total Shoulder Arthroplasty.
- ClinicalTrials.gov ID
- NCT01313741
- Acronym / sponsor ID
- Anchor Peg Study
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Knoxville Orthopedic ClinicUniversity, hospital or other
- Study start
- Apr 2011
- Primary completion
- Apr 2012 (estimated)
- Study completion
- Apr 2012 (estimated)
- First posted
- 14 Mar 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Two hundred patients will be analyzed both clinically (via validated outcomes measures) and radiographically (via 2 sets of standard radiographs) to determine the survival and degree of bone in growth of a novel all polyethelene glenoid component used in a standard FDA approved shoulder arthroplasty system.
Detailed description
Methods and Materials: The standard of care in my practice and most practices is to have arthroplasty patients return for an annual clinical and radiographic evaluation. We are asking our patients that choose to enroll in the study to simply return for routine "standard of care" follow up. The only deviation from this standard of care is the method by which we obtain the xrays. In this study we will obtain true AP (anterior/posterior) and axillary views on there return visit. These are our normal "standard of care" xrays. The only difference is that we are going to obtain these Xrays using fluoroscopic guidance. The reason we are using fluoroscopic guidance is that we want to make sure that the xrays are perfect with the beam oriented tangential to the backside of the glenoid. This will allow us to see any lucencies behind the glenoid and allow us to truly assess for any loosening. Standard Xrays attempt to have the beam oriented tangential to the glenoid but just small deviations can underestimate any potential lucent lines. This will expose the study subjects to small amounts of radiation that would be outside the "standard of care". The patients will be informed of this and the dose recorded. The fluoroscopy procedure will take about 15-20 minutes, but the total radiation exposure for the activities performed will be up to, but not more than three minutes. The total radiation will be less than 3 rem. A licensed radiology technologist (RT) employed by the hospital will perform the fluoroscopy procedures and the Xrays. Jeff Jarnagin PA or Edwin Spencer MD will be present at all times during the fluoroscopy procedure. Both Dr Spencer and Jeff Jarnagin have been involved in other similar studies and have completed "training in human research subject protection". Subjects will be provided proper shielding (lead apron) throughout the activities. The licensed radiology technologist at the hospital will have the final responsibility for providing proper shielding.
As with every clinical study, there may be some risks. Since the fluoroscope emits X-rays, subjects will be exposed to radiation. During fluoroscopy, the actual dose of radiation exposure that will be administered, is within minimal risk limits and will be much lower than those known to produce detectable health effects. For this study, the fluoroscopy machine will be on for up to, but not more than, 3 minutes total and the amount of radiation will not exceed 3 rem which includes the radiation from the standard Xrays. According to published literature, exposure risks below 5-10 rem are minimal. Health effects have not been consistently demonstrated for radiation exposure below 10 rem.
Subjects will also fill out 2 data sheets. One is for the PENN score and the other is for the ASES (Association of Shoulder and Elbow Surgeons) score which are validated clinical outcomes measures. These forms are routinely filled out at their annual clinical visits and are considered standard of care.
Data Analysis: The radiographs will be independently evaluated by 2 different board certified radiologists blinded to the clinical results and names of the patients. The films will be re-evaluated by each radiologist (they will be blinded to their initial reading) and the average of their results will be recorded. The clinical ASES and PENN scores will be recorded and differences in the preoperative and postoperative scores will be reported. Statistical analysis such as a students t test is not necessary as we are not comparing two groups however simple descriptive statistics will be used to report the change in ASES and PENN scores and most importantly the presence or absence of lucent lines and location of any lucencies. The lucent lines will be graded according to the method developed by Lazarus et al.4 The medical records and Xray data will be kept as confidential as possible under current local, state, and federal laws. The researchers will examine the medical records for information related to both of the shoulders and the study data. The medical records that identify the subject and the consent form will be reviewed by the researchers. The results of this research project may be presented at meetings or in publications. The identity of the subject will not be disclosed in any presentation or publication.
The Xrays will be stored in a secure place at the Knoxville Orthopaedic Clinic. These Xrays will be accessible by only approved personnel. They will be kept indefinitely for the possibility of future use in research or publications.
Personnel who will have access to your information include:
- Jeff Jarnagin PA (Assistant to Dr Spencer)
- Dr. Edwin Spencer, PI (Orthopaedic Surgeon)
Risk Analysis: The only risk involved is the extra amount of radiation required to obtained the floroscopically guided Xrays. As stated above the maximum amount of radiation is 3 rem which includes the radiation from the standard Xrays. According to published literature, exposure risks below 5-10 rem are minimal. Health effects have not been consistently demonstrated for radiation exposure below 10 rem. To protect the subjects a licensed radiology technologist (RT) employed by the hospital will perform the fluoroscopy procedures and the Xrays. Jeff Jarnagin PA or Edwin Spencer MD will be present at all times during the fluoroscopy procedure. Subjects will be provided proper shielding (lead apron) throughout the activities. The licensed radiology technologist at the hospital will have the final responsibility for providing proper shielding.
The benefits to the patient is for the researchers (and readers of any published data) to garner a better understanding of the best method to resurface the glenoid in a TSA. Many patients require bilateral operations and therefore it could directly benefit a few patients but essentially this project is designed to gather information for the greater good of all patients who require a TSA.
Subject Identification, Recruitment And Consent: Subjects will be identified by a unique identification number analogous to that used by the Knoxville Orthopaedic Clinic. Subjects will be called by either Dr Edwin E Spencer Jr MD (PI) or his assistant Jeff Jarnagin PA and asked to be involved or participate. The patients will be made aware that participation in the study is completely voluntary and that participation does not affect their future access to care by Dr Spencer. Informed consent will be reviewed over the phone and in person when they come in for Xrays by Dr Spencer or his assistant Jeff Jarnagin PA. Attached is our consent form. Once the subject has completed the xray evaluation and completed the clinical forms, they will be paid the $50 stipend. The subject will incur no cost for participation in the study. Insurance carriers will not be billed for any part of the study. The money for the patients will come from the study sponsor DePuy Inc. The xrays including the floroscopy and radiologists' readings will be paid for by the study sponsor DePuy. The surgeon, Dr Spencer, will not be paid for his time and effort and is donating his time to science and the greater good.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single arm shoulder arthroplasty | Experimental | Device: Shoulder arthroplasty with anchor peg glenoid |
Who may qualify
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Shoulder arthroplasty with anchor peg glenoidShoulder arthroplasty with anchor peg glenoid | Device | Single arm shoulder arthroplasty |
Primary outcome
ASES Scores
Time frame: Every 3 months
Accepted validated clinical outcome measure
PENN Score
Time frame: 3 months
Accepted validated outcome measure
Radiographic integration of component
Time frame: 2 weeks, 6 weeks, 3 months, 2 years
Two sets of radiographs will be obtained to look for any signs of loosening and for bony integration of the component
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Mar 2011.
- Website for our clinicLink provided by the sponsor.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Shoulder arthroplasty with anchor peg glenoid in people with The Primary Disease Process Being Studied is Shoulder OA and the Effect of an All Polyethelene Glenoid Component on Shoulder Arthroplasty, run by Knoxville Orthopedic Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Mar 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Edwin E Spencer Jr, MD (865 450 1227, spencer9882@comcast.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ASES Scores (time frame: Every 3 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2011.